CART-19/22 is a type of cell therapy used in the trial for children, adolescents, and young adults with a specific type of leukemia called B cell precursor acute lymphoblastic leukemia (ALL). This therapy involves modifying the patient’s own immune cells, called T cells, to better recognize and attack cancer cells that have certain markers, CD19 and CD22, on their surface. The goal is to see if this treatment is safe and can be successfully given to patients whose disease has not responded to other treatments.

CART-NKG2D T is another cell therapy being tested in the trial for patients with a different type of leukemia known as T-cell acute lymphoblastic leukemia (T-ALL). In this therapy, T cells are modified to target cancer cells with a specific marker called NKG2D. This treatment uses T cells from a donor, rather than the patient’s own cells, to see if it can be safely administered and if it can help treat the disease in patients who have not responded to other treatments.

Acute Lymphoblastic Leukemia – This is a type of cancer that affects the blood and bone marrow, characterized by the overproduction of immature white blood cells, known as lymphoblasts. It primarily occurs in children, adolescents, and young adults. The disease progresses rapidly, leading to symptoms such as fatigue, fever, frequent infections, and easy bruising or bleeding. As the abnormal cells multiply, they crowd out healthy blood cells, impairing the body’s ability to fight infections and carry oxygen. The condition can be classified into B-cell or T-cell types, depending on the specific lymphocytes involved. Relapsed or refractory cases occur when the disease returns after treatment or does not respond to standard therapies.